THE RIGHT VISION. Focused right on cardiac surgery.

Transcription

1 NASDAQ Symbol: ATSI

2 SAFE HARBOR THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO NUMEROUS RISKS AND UNCERTAINTIES. SEE OUR SECURITIES AND EXCHANGE COMMISSION FILINGS FOR A DESCRIPTION OF MANY OF THE RISKS AND UNCERTAINTIES. THIS PRESENTATION HAS BEEN PREPARED SOLELY BY US AND IS SOLELY OUR RESPONSIBILITY. THIS PRESENTATION DOES NOT PURPORT TO BE COMPREHENSIVE OR TO CONTAIN ALL THE INFORMATION THAT YOU MAY DESIRE IN EVALUATING AN INVESTMENT IN OUR SHARES. YOU SHOULD NOT CONSTRUE THE CONTENTS OF THIS PRESENTATION AS INVESTMENT, TAX OR LEGAL ADVICE. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION TO BUY ANY OF OUR SHARES IN ANY STATE OR OTHER JURISDICTION OR TO ANY PERSON IF SUCH AN OFFER OR SOLICITATION IS UNLAWFUL OR UNAUTHORIZED. 2

3 THE RIGHT VISION Focused right on cardiac surgery. 3

4 ATS BUSINESS THESIS Worldwide Demand Aging Global Population = Structural = Heart Disease Atrial Fibrillation Heart Valve Disease Cardiac Surgeon Centered Superior Products 4

5 ATS MEDICAL Core Competencies Superior Product Solutions Heart Valve Therapy ATS Open Pivot Mechanical Valves ATS 3f Tissue Valves ATS Simulus Valve Repair Products Atrial Fibrillation ATS CryoMaze Surgical Ablation System 5

6 STRATEGIC FOCUS - MIS Minimally Invasive Surgery (MIS) Friendly Technology Traditional Open-Chest MIS Approach 6

7 EXECUTIVE TEAM Mike Dale, President & CEO Endocardial Solutions, Cyberonics, St. Jude Medical, Edwards Laboratories James L. Cox, M.D., Medical Director Emeritus Evarts A. Graham Professor and Chief, Division of Cardiothoracic Surgery Washington University School of Medicine Mike Kramer, CFO CABG Medical, ECOLAB, Ernst & Young Astrid Berthe, VP of Regulatory and Quality Assurance 3f Therapeutics, Medtronic, Baxter Jeremy Curtis, VP of Marketing GE Healthcare, CHIQUITA Brands International David Elizondo, VP R & D and Clinical Affairs Boston Scientific, Cryolife, St. Jude Medical Thad Coffindaffer, VP US Sales Thermo Cardiosystems, Thoratec, GE J. Henry Kuper, Director EMEA Sales St. Jude Medical, Eli Lilly 7

8 EXPANDING MARKET OPPORTUNITIES ATS Revenue Opportunity Growth rates of markets entered since 2004 Tissue Heart Valves 5-7% Surgical AFIB Ablation 20%+ Mitral Valve Repair 5-7% Market data sources: Millenium Research Group, Health Research International and Management 8

9 A GLOBAL PRESENCE U.S. Revenue: $26M ( 08 Est.) Growth: 39% ( 08 Est.) EMEA Revenue: $24M ( 08 Est.) Growth: 30% ( 08 Est.) ACLA Revenue: $14M ( 08 Est.) Growth: 13% ( 08 Est.) 9

10 REVENUE HISTORY ($ Millions) 10

11 GROSS MARGIN HISTORY 11

12 EXPANDING INTO HIGH GROWTH MARKETS 6 Product Launches by 12/31/08 12

13 MECHANICAL VALVES ATS Open Pivot Mechanical Heart Valve $313M global market 13% worldwide market share- consistent share growth 63% of ATS revenue Growth Strategy Open Pivot = clotting = less anti-coagulation Use AP360 to expand US position 2008 Milestones Late Q1 AP360 US product launch Exceed 20% global procedure share Complete final Forcefield proof of concept study Strategic Opportunities Forcefield = No anti-coagulation = One Valve for Life solution Extend 3f Enable suture-less platform to Open Pivot 13

14 BLOOD AND MATERIALS INTERACTIONS Forcefield Background Artificial materials exposed to blood initially and spontaneously adsorb a film of plasma components, primarily protein Initial blood surface interactions with prosthetic valves and other cardiovascular material devices are dominated by plateletsurface interactions (thrombus formation) Project Objective: Use patient s own blood to inhibit blood cell component adhesion, by encouraging a more natural blood vs. materials interface Life-long heart valve without need for anti-coagulation therapy James M. Anderson and Frederick J. Schoen. Interactions of blood with artificial surfaces. Current Issues in Heart Valve Disease, THROMBOSIS, EMBOLISM AND BLEEDING 1992; Chapter 2.3pp

15 BLOOD AND MATERIALS INTERACTIONS Forcefield Clinical Progress Forcefield Acute Human Experience Stent Results Forcefield Treated -No Platelets- Control -Platelet Aggregation- 15

16 TISSUE VALVES ATS 3f Tissue Valve $771M global market 130+ Issued & pending patents Growth Strategy Leverage Open Pivot brand Functionally superior tubular design Novel sutureless platform(s) 2008 Milestones First generation tissue valve approval in US Complete Enable trial enrollment in Europe Strategic Opportunities Enter largest market segment in valves Sutureless = disruptive potential 16

17 ATS 3f ENABLE AORTIC BIOPROSTHESIS Pivotal Trial Experience Implanted without sutures ~10 Min Nitinol frame expands to preset diameter to secure valve in position No leaks, no migration, superior hemodynamics Reduction in CPB and aortic x-clamp time Enables stopped heart less invasive surgery procedures 17

18 ATS 3f ENABLE AORTIC BIOPROSTHESIS Implant Procedure 18

19 VALVE REPAIR ATS Repair $150M global market Fastest growing segment 08 ~ 120% Growth Strategy Leverage Simulus technology Easy to Sew Robot friendly Line extension into remaining market segments 2008 Milestones Market launch Semi-rigid & Flexible-adjustable Strategic Opportunities Build upon less-invasive procedure advantage Leverage CryoMaze AFIB procedures 19

20 ATRIAL FIBRILLATION ATS Atrial Fibrillation $151M global revenue-emerging market Fastest growing market in cardiac surgery Dr. James Cox Medical Director Growth Strategy Cryo is THE source for Full Maze Full Maze required for success Leverage CRYO KOL s 2008 Milestones Strategic marketing programs Launch new enhanced clamp Stand-alone market introduction Strategic Opportunities Stand-alone market potential >$3B 20

21 ATRIAL FIBRILLATION U.S. Stand-Alone and Concomitant Opportunity Paroxysmal AF (PAF) Stand-Alone PAF Treatable by catheter ablation, surgical PVI or Maze 1,770,000 Concomitant PAF Treatable by surgical PVI or Maze 30,000 ~$75M Mkt Oppty Continuous AF (CAF) Stand-Alone CAF Treatable by surgical bilateral Maze procedure 1,170,000 ~$5.9B Mkt Oppty Concomitant CAF Treatable by surgical bilateral Maze procedure 35,000 ~$87.5M Mkt Oppty Stand-Alone AF Concomitant AF Note: Assumes ~$5k/treatment for Stand-Alone and $2.5k/treatment for Concomitant 21

22 ATRIAL FIBRILLATION MIS Stand-Alone ATS CryoMaze Procedure Video 22

23 ATRIAL FIBRILLATION MIS Stand-Alone Clinical Results: Curative Proof of Potential Stand-Alone CryoMaze Study Presented 1/12/2008 (East Carolina University) Patient Population: Patients by Disease State: Procedure Summary: Patient Follow-up Methods: Results: 57 Patients Continuous 90% Paroxysmal 10% ATS CryoMaze Probe Full, Bi-lateral Maze da Vinci Robot Cardio-pulmonary bypass Cardionet 45 Patients EKG 10 Patients Holter Monitor 2 Patients 85.9% in sinus rhythm 8.8% in sinus rhythm w/ medication 23

24 ATS GROWTH STRATEGY Delivering Innovative Products and Services Building the Brand Value/Equity Leveraging the Infrastructure 24

25 Open Pivot Heart Valve Prosthesis Electronic sensing, monitoring and/or pacing circuitry in heart valves Anti-coagulation and Electronic sensing, monitoring and/or pacing circuitry in heart valves Manufacturing technique Laser Method patent regarding the use of a laser to cut tissue Cut edges are melted to discourage delamination or fraying Beneficial as tissue valves move A Strong Portfolio of 140+ Issued and Demineralization system for conductive medical devices (ForceField anti-platelet technology) Pending Patents Covering Heart Valve PARSUS ultrasonic technology for blood Therapy filtration and Cardiac Surgical towards new and Ablation more Tubular Heart Valve Technology complicated designs, especially Easily compressed and expanded, in the field of minimally invasive ideal for creating less invasive & percutaneous valves valves Venpro Venous Valve IP (Licensed Minimally Invasive Heart Valve & Owned) Designs Tricuspid Valve Regurgitation Trans-apical Valve Technologies Methods and devices for Valve Delivery preventing tricuspid valve Distal Embolic Protection regurgitation Imaging (using IVUS, etc) 25

26 TRACK RECORD OF GROWTH ($ Millions) 26

27 CONTINUED GROWTH AND DIVERSIFICATION Note: Q2 08 figures are approximate and preliminary 27

28 Q SALES PRE-RELEASE SUMMARY Accelerating Growth Note: Q2 08 figures are approximate and preliminary 28

29 PROGRESS TOWARD PROFITABILITY ($ Millions) Diversified revenue stream Continuous margin improvement Leveraged distribution infrastructure Projected Profitability in Q

30 Thank you!